anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602
Term · Oncology and biomedicine · MLC-T-ONC-011106
A bifunctional antibody fusion protein composed of an agonist antibody targeting the variable (V) beta 6 (Vb6) and beta 10 (Vb10) regions of the T cell receptor (TCR) and fused to the cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602 selectively targets and binds to the Vb6 and Vb10 regions of the TCR expressed on a subset of alpha/beta T cells, thereby activating and expanding these alpha/beta T-cells. This promotes T-cell-mediated immune responses against tumor cells. IL-2 targets and binds to the IL-2 receptor IL2R and activates IL-2/IL-2R-mediated signaling, which further activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This further enhances T-cell-mediated cytotoxic immune responses against tumor cells. Alpha/beta T cells play an important role in the adaptive immune response.
| Identifier | MLC-T-ONC-011106 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-TCR Vb/IL-2 bispecific antibody fusion protein STAR0602; anti-TCR Vb6/Vb10/IL-2 bifunctional antibody-fusion molecule STAR0602 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011106",
"term": "anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602",
"field": "Oncology and biomedicine",
"definition": "A bifunctional antibody fusion protein composed of an agonist antibody targeting the variable (V) beta 6 (Vb6) and beta 10 (Vb10) regions of the T cell receptor (TCR) and fused to the cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602 selectively targets and binds to the Vb6 and Vb10 regions of the TCR expressed on a subset of alpha/beta T cells, thereby activating and expanding these alpha/beta T-cells. This promotes T-cell-mediated immune responses against tumor cells. IL-2 targets and binds to the IL-2 receptor IL2R and activates IL-2/IL-2R-mediated signaling, which further activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This further enhances T-cell-mediated cytotoxic immune responses against tumor cells. Alpha/beta T cells play an important role in the adaptive immune response.",
"synonyms": [
"anti-TCR Vb/IL-2 bispecific antibody fusion protein STAR0602",
"anti-TCR Vb6/Vb10/IL-2 bifunctional antibody-fusion molecule STAR0602"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-tcr-vb6-vb10-il-2-antibody-fusion-protein-star0602/"
}
Record 2,249 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.